DE
Journey Medical Corporation
DERM · NASDAQ
$6.31 +6.05% (+$0.36)
1M -11.00%
Market Cap $163.8M
P/E Ratio -
Div. Yield -
ROE 20.23%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
23 /100
Expensive EV/EBITDA 88.51x
P/S 2.40x
P/B 5.10x
Growth
22 /100
Declining Rev. growth 5.66%
Book val. growth 23.32%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 62.24%
Net margin 8.95%
FCF margin 10.99%
Quality
9 /100
Poor ROIC 5.23%
ROE 20.23%
Asset turnover 0.69x
Debt
66 /100
Moderate Debt/Equity 0.80x
Current ratio 1.59x
Net debt/EBITDA -0.06x
Stability
35 /100
Moderate Beta 1.10x
Rev. volatility 21.95%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about DERM
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Claude Maraoui
Employees
58
Headquarters
Scottsdale
Upcoming events
11 NOV
Earnings
Upcoming earnings report